Oncolytics Biotech Inc T.ONC

Pfizer acquired preclinical Trillium for US$ 2.3 Bln

[Noteable]

https://www.fiercebiotech.com/biotech/pfizer-and-trillium-how-a-25m-investment-led-to-a-2-3b-buyout

[Noteable]

With Pfizer's acquisition of the preclinical CD47 company Trillium Therapeutics for US$ 2.3 Billion, and with today's news that Roche financially supported CD47 start-up company Arch Oncology has given up and laid off all of its employees, suggesting that CD47 is not a viable cancer target, and with both Pfizer and Roche facing looming patent cliffs in the foreseeable future, ONCY's

[Noteable]

January 26, 2022 : "....Gilead, ... has halted some studies of its anti-CD47 project magrolimab after seeing adverse events. This is another blow to Gilead’s deal strategy - it paid $4.9 bn for Forty Seven's (CD47) magrolimab in 2020 – but the news could also make Pfizer nervous. The pharma giant recently made its own CD47 move buying Trillium for $2.3bn"  https:

[Noteable]

The development of CD47 antibodies is primarily hampered by their on-target binding to red blood cells (RBCs). Therefore, various CD47 antibodies in their clinical development are found to be susceptible to severe anemia and other hematologic side effects. As a result, many CD47 antibody programs have been either terminated in early clinical trials or faced drug safety challenges in hematological

[Noteable]

CD47-targeting antibodies in development were though to be designed to bind better to the CD47 receptor in acidic conditions, like those found in the tumor microenvironment, while binding less to the CD47 found on normal cells, including red blood cells, however what has been recently revealed is that CD47's increased binding to red blood cells resulted in severe hematological side effects

[Noteable]

January 13, 2023 - From Forbes Review of the story contained in the newly release novel entitled " For Blood and Money " subtitled " Billionaires, Biotech, and the Quest for a Blockbuster Drug" comes that following  "Rothbaum grew amazed with how the human body worked. He marveled at the connections and mechanisms, the chain reactions and the interconnectedness